During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50...
Ambitious new medium-term targets set for Scopes 1, 2, and 3SBTi confirms compatibility of science-based reduction targets with Paris Climate...
Crosetto’s technology was recognized as a breakthrough invention by FERMILAB and awarded a $1 million U.S. DOE grant; these achievements,...
Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports full-year revenue...
TULSA, Okla., Feb. 12, 2026 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have announced an investment in BioReact, an...
SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire...
Burlington, Ontario--(Newsfile Corp. - February 11, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian...
BLUE BELL, Pa., Feb. 11, 2026 /PRNewswire/ -- Elevate Healthcare Marketing, a leading healthcare marketing agency known for delivering insight-driven,...
Members of the SEISMIC project team Members of the SEISMIC project team SEISMIC Kickoff Meeting at Philips in Best, the...
Members of the SEISMIC project team Members of the SEISMIC project team SEISMIC Kickoff Meeting at Philips in Best, the...
Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has requested a Type...
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary...
SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health securityStrategic...
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and...
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT...
Burlington, Ontario--(Newsfile Corp. - February 10, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") ,...
SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders,We have completed our AI platform in the last 12 months and...